Everything below concerns Lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical lyophilized research form. |
| Solubility | Soluble in DMSO; limited in water | Depends on purity and salt form. |
| Storage temperature | -20 °C or lower | Desiccated and protected from light. |
| Analytical method | RP-HPLC and LC-MS | Common for purity and identity. |
| Regulatory status | Research chemical in many countries | Not widely approved as a medicine. |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
=== February === 1 February – A Statutory Instrument paving the way for the Northern Ireland Executive to be re-established is passed by the House of Commons. Conservative MP Mike Freer announces he is standing down from Parliament at the next election following death threats and an arson attack on his constituency office. Downing Street describes the situation as "an attack on democracy". Addressing a meeting of business leaders, Shadow Chancellor Rachel Reeves says that Labour would not increase corporation tax if elected, but may cut it to boost "competitiveness". Penny Mordaunt, the Leader of the House of Commons, has argued plans to expand the Senedd from 60 to 96 MSs would be the equivalent of expanding the House of Commons from 650 to 2,000 MPs. MP Christina Rees is readmitted to the Labour Party but announces her retirement at the next general election. 2 February – Senior Labour MP Darren Jones confirms that the party has ditched its commitment to spend £28bn a year on green investment schemes if it wins the next general election. 3 February – 2024 Northern Ireland Executive Formation: The Northern Ireland Assembly meets to elect a new Speaker. Edwin Poots, a former leader of the DUP, is chosen to be the Assembly's 7th Speaker. The Northern Ireland Executive is restored after the DUP ends its two year boycott; Sinn Féin's Michelle O'Neill is nominated as First Minister, becoming the first nationalist politician to hold the post, while the DUP's Emma Little-Pengelly is appointed deputy. SDLP MLA Matthew O'Toole is nominated as Leader of the Opposition.
=== OS Fund === In October 2014, Johnson announced the launch of the OS Fund, which invests in early-stage science and technology companies and which he backed with $100 million of his personal capital.
In the USA, anethole is generally recognized as safe (GRAS). After a hiatus due to safety concerns, anethole was reaffirmed by Flavor and Extract Manufacturers Association (FEMA) as GRAS. The concerns related to liver toxicity and possible carcinogenic activity reported in rats. Anethole is associated with a slight increase in liver cancer in rats, although the evidence is scant and generally regarded as evidence that anethole is not a carcinogen. An evaluation of anethole by the Joint FAO/WHO Expert Committee on Food Additives (JECFA) found its notable pharmacologic properties to be reduction in motor activity, lowering of body temperature, and hypnotic, analgesic, and anticonvulsant effects. A subsequent evaluation by JECFA found some reason for concern regarding carcinogenicity, but there is currently insufficient data to support this. At this time, the JECFA summary of these evaluations is that anethole has "no safety concern at current levels of intake when used as a flavoring agent". In large quantities, anethole is slightly toxic and may act as an irritant.
=== Nutrition === Calcium is a common constituent of multivitamin dietary supplements, but the composition of calcium complexes in supplements may affect its bioavailability which varies by solubility of the salt involved: calcium citrate, malate, and lactate are highly bioavailable, while the oxalate is less. Other calcium preparations include calcium carbonate, calcium citrate malate, and calcium gluconate. The intestine absorbs about one-third of uncomplexed calcium consumed, and plasma calcium level is then regulated by the kidneys.
== History == Fascism and Freedom Movement was founded in 1989 as a political movement inside the Italian Social Movement, centered around Senator Giorgio Pisanò and his weekly Candido. Finally, it separated from the MSI on 25 July 1991. In 2009, it added the words National Socialist Party (NSP) to its original name. The movement has been sued several times for alleged reconstitution of the dissolved National Fascist Party. It refuses agreements and / or alliances with other neo-fascist parties, stressing categorically not to be classified as a right-wing party, and that similar parties do not sufficiently adhere to Fascist ideology. The party makes explicit reference to the ideals of the Italian Social Republic as corporatism and the nationalization of the economy. Their ideology is based on the thought of fascist leader Benito Mussolini, and has as its main objective the realization of Mussolini's strongly hierarchical corporate democracy based on social credit. The party is also in favor of a presidential republic, and expresses a strong sense of anti-Americanism and anti-Zionism. It is the only recognised party in Italy with the inscription "Fascismo" on its logo. Overall, it is an ultranationalist party with tendencies towards the Third Position and anti-capitalism.
Sources: en.wikipedia.org
== External links == Nonlinear Fracture Mechanics Notes by Prof. John Hutchinson, Harvard University Notes on Fracture of Thin Films and Multilayers by Prof. John Hutchinson, Harvard University Fracture Mechanics by Piet Schreurs, TU Eindhoven, The Netherlands
=== Other interventions === A 2024 review found that fecal microbiota transplantation may reduce pain intensity and improve fatigue and quality of life in patients with fibromyalgia, but evidence was insufficient at that stage to support use. Research on gut microbiome links with FM continues. Hyperbaric oxygen therapy (HBOT) has shown beneficial effects in treating chronic pain by reducing inflammation and oxidative stress. However, treating fibromyalgia with hyperbaric oxygen therapy is still controversial, in light of the scarcity of large-scale clinical trials. In addition, hyperbaric oxygen therapy raises safety concerns due to the oxidative damage that may follow it. An evaluation of nine trials with 288 patients in total found that HBOT was more effective at relieving fibromyalgia patients' pain than the control intervention. In most of the trials, HBOT improved sleep disturbance, multidimensional function, patient satisfaction, and tender spots. Negative outcomes (predominantly mild barotrauma (air pressure effect on ear or lung) that could be resolved spontaneously) were experienced by 24% of the patients, but they were not prevented from completing the treatment regimen, and no serious side effects, complications, or deaths were reported.
== Units == The SI unit of dynamic viscosity is the newton-second per metre squared (N·s/m2), also frequently expressed in the equivalent forms pascal-second (Pa·s), kilogram per meter per second (kg·m−1·s−1) and poiseuille (Pl). The CGS unit is the poise (P, or g·cm−1·s−1 = 0.1 Pa·s), named after Jean Léonard Marie Poiseuille. It is commonly expressed, particularly in ASTM standards, as centipoise (cP). The centipoise is convenient because the viscosity of water at 20 °C is about 1 cP, and one centipoise is equal to the SI millipascal second (mPa·s). The SI unit of kinematic viscosity is metre squared per second (m2/s), whereas the CGS unit for kinematic viscosity is the stokes (St, or cm2·s−1 = 0.0001 m2·s−1), named after Sir George Gabriel Stokes. In U.S. usage, stoke is sometimes used as the singular form. The submultiple centistokes (cSt) is often used instead, 1 cSt = 1 mm2·s−1 = 10−6 m2·s−1. 1 cSt is 1 cP divided by 1000 kg/m^3, close to the density of water. The kinematic viscosity of water at 20 °C is about 1 cSt. The most frequently used systems of US customary, or Imperial, units are the British Gravitational (BG) and English Engineering (EE). In the BG system, dynamic viscosity has units of pound-seconds per square foot (lb·s/ft2), and in the EE system it has units of pound-force-seconds per square foot (lbf·s/ft2). The pound and pound-force are equivalent; the two systems differ only in how force and mass are defined.
Mindlin (1928), engineer, Medal for Merit and ASME Medal recipient Harold Charles Bold (1929), botanist Jule Eisenbud (1929), psychiatrist known for research into parapsychology Theodore Lidz (1930), Sterling Professor of psychiatry at Yale; expert on schizophrenia Judd Marmor (1930), psychoanalyst and psychiatrist on homosexuality Herbert L. Anderson (1931), director of the Enrico Fermi Institute, professor of the University of Chicago Paul E. Queneau (1931), professor of metallurgical engineering at Dartmouth College Bernard Glueck Jr. (1933), psychiatrist, former president of the American Psychopathological Association Irving Kaplan (1933), chemist, professor at Massachusetts Institute of Technology Leo Rangell (1933), psychoanalyst; president of the International Psychoanalytical Association and the American Psychoanalytic Association John K. Lattimer (1935), urologist, ballistics expert, and inveterate collector Emanuel Papper (1935), anesthesiologist, dean of the Miller School of Medicine at the University of Miami 1969–1981 Norman Foster Ramsey Jr. (1935), winner of the Nobel Prize in Physics Robert Marshak (1936), president of the American Physical Society and president of the City College of New York Julian Schwinger (1936), winner of the Nobel Prize in Physics; posited the Schwinger effect Barry Commoner (1937), leading environmentalist, former editor of Science Illustrated magazine Francis J. Ryan (1937), professor of zoology at Columbia University Boris Jacobsohn (1938), professor of Physics at the University of Washington David B.
== Research == Stem cell therapy may represent a treatment for promoting the healing of diabetic foot ulcers. Diabetic foot ulcers develop their own, distinctive microbiota. Investigations into characterizing and identifying the phyla, genera, and species of nonpathogenic bacteria or other microorganisms populating these ulcers may help identify one group of microbiota that promotes healing. The recent advances in epigenetic modifications, with special focus on aberrant macrophage polarisation, are giving increasing evidence that epigenetic modifications might play a vital role in changing the treatment of diabetic foot ulcer in the near future.
Sources: en.wikipedia.org
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.
Mass spectrometry is commonly used to confirm molecular mass, while RP-HPLC estimates purity. These methods can be combined with amino acid analysis or NMR for further structural confirmation. A certificate of analysis alone does not guarantee independent verification.
Legality depends on the country and the intended use. In many places it is not approved as a drug and may be regulated as a research chemical. Buyers should check local laws and institutional policies before obtaining it.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.